

## **FOR IMMEDIATE RELEASE**

### **Remy Biosciences Unveils Trio of Pioneering Transdermal Patches, Offering Groundbreaking Solutions for Menstrual Cramps, General Pain Relief, and Psilocybin Therapy**

[Santa Ana, California – April 19, 2024] – Remy Biosciences, Inc., a leader in advanced drug delivery systems, today announced the publication of three patent applications for its innovative transdermal patches: the Reya Patch for menstrual cramps, a general pain relief patch, and a psilocybin therapy patch. Each patch incorporates the exclusive Remy Biosciences Biodermal Technology™, marking a significant advancement in non-invasive medical treatments. The Reya patch, now available at [www.getreya.com](http://www.getreya.com), represents a revolutionary approach to menstrual pain relief, relieving up to 100% of pain due to severe menstrual cramps in a double-blind, placebo-controlled trial. It significantly outperformed the placebo across various pain relief and quality-of-life metrics.

Justin Brown, CEO, said, “We are deeply committed to continually driving innovation in drug delivery, and these patents represent that work. It is especially exciting to bring that innovation to consumers in our Reya patch that is helping women relieve menstrual pain significantly. We are dedicated to getting our science out of the lab, and into products that can truly help people.”

The general pain relief patch stands out for its superior efficacy with 92% less active drug used compared to market leaders, offering a potent yet safer alternative for managing pain. The psilocybin transdermal patch is designed to counteract the gastrointestinal distress commonly associated with oral delivery. This allows for direct absorption into the bloodstream, bypassing the digestive system entirely, which enhances the therapeutic potential and patient comfort.

#### **Quotes from Inventors:**

Brent Cahill, co-inventor of the patches, stated, “We are thrilled that these patents have been published. They represent a significant stride forward in the treatment of some of the world’s most prevalent health concerns. We are particularly excited that our first commercially available DTC product, Reya, is now recognized via published patent.” Mark Burleson, co-inventor, added, “The patents signify major strides in our research & development. As we continue to innovate, we are confident that our technology will improve quality of life for people all around the globe.”

#### **About Remy Biosciences, Inc.:**

Founded on the principles of innovation and accessibility, Remy Biosciences creates vital medicines and supplements with its cutting-edge transdermal and sublingual technology platforms. These platforms are designed to provide safe, highly effective controlled-dose delivery systems. Remy Biosciences is dedicated to the development of “the next generation of advanced drug delivery.”

**For further information, please visit [www.remybiosciences.com](http://www.remybiosciences.com)**

For more information:

Brent Cahill

Executive Vice President

(949) 444-1358

[brentc@remybiosciences.com](mailto:brentc@remybiosciences.com)